Primary prevention of cardiovascular disease with hormone replacement therapy

References

• Nichols M, Townsend N, Luengo-Fernandez R, et al. European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia, Antipolis
   Google Scholar
• World Health Organization. Global burden disease estimates; DALY estimates, 2000–2012. World Health Organization, 2014. www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html
   Google Scholar
• Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243–52
   PubMed Web of Science ®Google Scholar
• Nilsson S, Molstad S, Karlberg C, Karlsson JE, Persson LG. No connection between the level of exposition to statins in the population and the incidence/mortality of acute myocardial infarction: an ecological study based on Sweden’s municipalities. J Negat Results Biomed 2011;10:6
   PubMedGoogle Scholar
• Dorresteijn JA, Visseren FL, Ridker PM, et al. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J 2011;32:2962–9
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Andreotti F, ten Berg JM, et al. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis. J Am Coll Cardiol 2014;64:319–27
   PubMed Web of Science ®Google Scholar
• Sutcliffe P, Connock M, Gurung T, et al. Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trials. PLoS One 2013;8:e81970
   Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38:199–210
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group .JAMA 1998;280: 605–13
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. A “window of opportunity”: the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res 2011;1379:244–52
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 2015;22:391–401
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535–45
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–57
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345: e6409
   PubMed Web of Science ®Google Scholar
• Mosekilde L, Hermann AP, Beck-Nielsen H, Charles P, Nielsen SP, Sorensen OH. The Danish Osteoporosis Prevention Study (DOPS): project design and inclusion of 2000 normal perimenopausal women. Maturitas 1999;31:207–19
   PubMed Web of Science ®Google Scholar
• Shapiro S. Recent epidemiological evidence relevant to the clinical management of the menopause. Climacteric 2007;10(Suppl 2): 2–15
   PubMed Web of Science ®Google Scholar
• Rosano GM, Webb CM, Chierchia S, et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000;36:2154–9
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Hapgood JP, Winer S, Mishell DR, Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171–208
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Dinger JC, Heinemann LA, Mohner S, Thai DM, Assmann A. Breast cancer risk associated with different HRT formulations: a register-based case-control study. BMC Womens Health 2006; 6:13
   PubMedGoogle Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
   PubMed Web of Science ®Google Scholar
• Bluming AZ, Tavris C. Hormone replacement therapy: real concerns and false alarms. Cancer J 2009;15:93–104
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011;14:633–6
   PubMed Web of Science ®Google Scholar
• Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303–11
   PubMed Web of Science ®Google Scholar
• La VC, Giordano SH, Hortobagyi GN, Chabner B. Overweight, obesity, diabetes, and risk of breast cancer: interlocking pieces of the puzzle. Oncologist 2011;16:726–9
   PubMed Web of Science ®Google Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Eisenberger A, Westhoff C. Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol 2014; 142:76–82
   PubMed Web of Science ®Google Scholar
• L’Hermite M. HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT. Climacteric 2013; 16(Suppl 1):44–53
   PubMed Web of Science ®Google Scholar
• Simon JA. What’s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):3–10
   PubMed Web of Science ®Google Scholar
• Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965–76
   PubMed Web of Science ®Google Scholar
• Archer DF, Oger E. Estrogen and progestogen effect on venous thromboembolism in menopausal women. Climacteric 2012;15:235–40
   PubMed Web of Science ®Google Scholar
• Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638–42
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Vandromme J, Antoine C. Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol 2013;9: 216–27
   PubMed Web of Science ®Google Scholar
• Sohrabji F, Williams M. Stroke neuroprotection: oestrogen and insulin-like growth factor-1 interactions and the role of microglia. J Neuroendocrinol 2013;25:1173–81
   PubMed Web of Science ®Google Scholar
• Petrone AB, Simpkins JW, Barr TL. 17beta-estradiol and inflammation: implications for ischemic stroke. Aging Dis 2014; 5:340–5
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Lokkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257–66
   PubMed Web of Science ®Google Scholar
• Lobo RA. The risk of stroke in postmenopausal women receiving hormonal therapy. Climacteric 2009;12(Suppl 1):81–5
   PubMed Web of Science ®Google Scholar
• Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an analysis from the atrial fibrillation follow-up investigation of rhythm management trial. Stroke 2014;45: 3076–9
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1–9
   PubMed Web of Science ®Google Scholar
• Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990; 76:290–5
   PubMed Web of Science ®Google Scholar
• Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983;309: 1405–7
   PubMed Web of Science ®Google Scholar
• Aitken JM, Hart DM, Lindsay R. Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. Br Med J 1973;3:515–18
   PubMed Web of Science ®Google Scholar
• Hedlund LR, Gallagher JC. The effect of age and menopause on bone mineral density of the proximal femur. J Bone Miner Res 1989;4:639–42
   PubMed Web of Science ®Google Scholar
• Palacios S, Neyro JL, Fernandez de CS, Chaves J, Rejas J. Impact of osteoporosis and bone fracture on health-related quality of life in postmenopausal women. Climacteric 2014;17:60–70
   PubMed Web of Science ®Google Scholar
• Bianchi ML, Orsini MR, Saraifoger S, Ortolani S, Radaelli G, Betti S. Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes 2005;3:78
   PubMedGoogle Scholar
• Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol 2014;142:68–75
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW, MacLennan AH. Quality of life and the role of menopausal hormone therapy. Climacteric 2012;15: 213–16
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42–52
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804
   PubMed Web of Science ®Google Scholar